Displaying 96 (all) recruiting clinical trials.
-
A Randomized Open-Label Multicenter Phase 3 Trial of Domvanalimab Zimberelimab and Chemotherapy Versus Nivolumab and Chemotherapy in Participants with Previously-Untreated Locally Advanced Unresectable or Metastatic Gastric Gastroesophageal Junction and Esophageal Adenocarcinoma
This study is designed for patients who have Untreated Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma
This is a phase 3 ...
-
A randomized parallel-group double-blind placebo-controlled multicenter Phase III trial to investigate the efficacy and safety of secukinumab 300 mg administered subcutaneously versus placebo both in combination with a glucocorticoid taper regimen i
The purpose of this research study is to demonstrate if secukinumab 300 mg and secukinumab 150 mg administered as an injection under the skin is ... -
PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING EFFICACY AND SAFETY OF MOSUNETUZUMAB IN COMBINATION WITH LENALIDOMIDE IN COMPARISON TO RITUXIMAB IN COMBINATION WITH LENALIDOMIDE IN PATIENTS WITH FOLLICULAR LYMPHOMA AFTER AT LEAST ONE LINE OF SYSTEMIC THERAPY
The purpose of the study is to evaluate the efficacy and safety of mosunetuzumab in combination with lenalidomide (M +Len) compared with rituximab in combination ... -
A Multicenter Randomized Double-Blind Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of BIIB059 in Adult Participants With Active Systemic Lupus Erythematosus Receiving Background Non-Biologic Lupus Standard of Care
The purpose of the study is to investigate if the investigational study drug BIIB059 can reduce disease activity and inflammation in people with active systemic ... -
A PHASE 3 RANDOMIZED PLACEBO-CONTROLLED DOUBLE-BLIND MULTICENTER TRIAL OF SELINEXOR IN MAINTENANCE THERAPY AFTER SYSTEMIC THERAPY FOR PATIENTS WITH P53 WILD-TYPE ADVANCED OR RECURRENT ENDOMETRIAL CARCINOMA
This is a study to test a drug called selinexor for patients with EC (endometrial carcinoma). The drug will be given to patients who have ...
-
Randomized Double-blind Placebo-Controlled Multicenter Phase 3 Study to Evaluate the Safety Tolerability and Efficacy of XEN1101 as Adjunctive Therapy in Focal-Onset Seizures
In this research a study drug named XEN1101 is being tested for the treatment of seizures. XEN1101 is a study drug because its safety, effectiveness ... -
Roadster 3
The purpose of this research study is intended to evaluate real world usage of the ENROUTE® Transcarotid Stent when used with the ENROUTE® Transcarotid Neuroprotection ... -
A Phase 3 Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants with Active Systemic Lupus Erythematosus (POETYK-SLE-2)
This study is a double-blinded 52-week clinical trial to evaluate the efficacy and safety of deucravacitinib in adult participants with active Systemic Lupus Erythematosus (SLE ... -
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA
This is a phase 3 clinical trial that compares the effectiveness of two different treatment options in patients who have undergone surgery to remove high-risk ...
-
A Randomized Double-blind Placebo-controlled Phase 3 Study to Evaluate the Effect of Resmetirom on Liver-related Outcomes in Patients with Well-compensated (Child-Pugh A) Non-alcoholic Steatohepatitis (NASH) Cirrhosis
A Randomized Double-blind Placebo-controlled study to determine the effect of randomized, once-daily, oral administration of 80 mg resmetirom versus matching placebo on patients with well-compensated ...